Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: 28 brokerages give Edwards Lifesciences an average recommendation of "Moderate Buy" (16 buys, 9 holds, 3 strong buys) with a 12‑month average target of $95.65 and several firms recently raising targets to $100–$110.
• Earnings beat and guidance: Q1 results topped estimates with EPS $0.78 vs. $0.73 and revenue $1.65B vs. $1.60B (revenue +16.7% YoY); the company set FY2026 EPS guidance of $2.95–3.05 and Q2 guidance of $0.70–0.76.
• Insider selling: Insiders sold a total of 86,058 shares worth about $7.12M over the last quarter (insiders now own 0.31% of shares), including notable VP sales, some executed under Rule 10b5‑1 plans.

Shares of Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-eight brokerages that are currently covering the firm, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $95.6522.

Several equities research analysts have recently issued reports on the company. BTIG Research raised their price objective on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, April 24th. Barclays reissued an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Wells Fargo & Company lifted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 86,058 shares of company stock worth $7,118,636 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $27,000. Finally, True Wealth Design LLC increased its holdings in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after acquiring an additional 259 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $82.28 on Wednesday. The business's fifty day moving average price is $81.94 and its two-hundred day moving average price is $82.41. The stock has a market cap of $47.43 billion, a PE ratio of 43.76, a price-to-earnings-growth ratio of 2.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences has a one year low of $72.30 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The company had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. During the same period last year, the company earned $0.64 EPS. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences will post 2.99 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.